Form 4: Neogenomics Executive Alicia Olivo Reports Stock Transactions
SEC Form 4 Filing
Alicia Olivo, General Counsel of Neogenomics, reports the vesting of restricted stock units and subsequent tax withholding, impacting her beneficial ownership of company stock.
Summary
- On May 11, 2024, Alicia Olivo, General Counsel of Neogenomics, reported transactions involving the company's stock.
- Ms. Olivo acquired 6,502 shares of common stock through the vesting of restricted stock units at a price of $0.
- Simultaneously, 1,584 shares were disposed of to cover tax withholding obligations at a price of $14.86 per share.
- Following these transactions, Ms. Olivo's direct ownership increased to 45,916 shares.
- The report also details Ms. Olivo's holdings of various stock options and performance stock units with different exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing detailing stock transactions by an insider. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Future Outlook
The document details future vesting dates for restricted stock units, performance stock units, and stock options, indicating potential future changes in Ms. Olivo's holdings.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common compensation practices for executives in publicly traded companies, including those in the diagnostics and biotechnology sectors.
- Companies like Exact Sciences, Guardant Health, and Invitae also utilize similar equity-based compensation plans to align executive interests with shareholder value.
- The vesting schedules and performance-based criteria outlined in the document are typical for such grants, designed to incentivize long-term performance and retention.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
- The vesting of equity awards incentivizes the executive to contribute to the company's success, potentially benefiting all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options, vesting ratably over four years. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options, vesting ratably over four years. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options, vesting ratably over four years. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options, vesting ratably over four years. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options, vesting ratably over four years. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options, vesting ratably over four years. |
| 05/11/2023 | Ms. Olivo was granted 19,508 restricted stock units and 36,508 stock options, vesting ratably over three years. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units, vesting ratably over three years. |
| 05/11/2024 | Reported transactions: vesting of 6,502 restricted stock units and disposition of 1,584 shares for tax withholding. |
| 05/14/2024 | Date of the report filing. |
| 05/11/2026 | Performance Stock Unit vesting date. |
| 02/23/2027 | Performance Stock Unit vesting date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.